KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Minority Interest (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Minority Interest readings, the most recent being $4.0 million for Q1 2026.

  • On a quarterly basis, Minority Interest fell 42.86% to $4.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $4.0 million, a 42.86% decrease, with the full-year FY2025 number at $4.0 million, down 98.82% from a year prior.
  • Minority Interest hit $4.0 million in Q1 2026 for Teva Pharmaceutical Industries, roughly flat from $4.0 million in the prior quarter.
  • In the past five years, Minority Interest ranged from a high of $916.0 million in Q1 2022 to a low of $4.0 million in Q4 2025.
  • Median Minority Interest over the past 5 years was $461.0 million (2023), compared with a mean of $456.0 million.
  • Biggest five-year swings in Minority Interest: dropped 6.05% in 2022 and later tumbled 98.82% in 2025.
  • Teva Pharmaceutical Industries' Minority Interest stood at $794.0 million in 2022, then fell by 26.7% to $582.0 million in 2023, then crashed by 41.58% to $340.0 million in 2024, then tumbled by 98.82% to $4.0 million in 2025, then changed by 0.0% to $4.0 million in 2026.
  • The last three reported values for Minority Interest were $4.0 million (Q1 2026), $4.0 million (Q4 2025), and $7.0 million (Q1 2025) per Business Quant data.